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Abstract
Background: Recently few studies tried to confirm the association between AF and lipoprotein(a) (Lp(a)), however
the results remained conflicted. In present study we evaluated the possible interaction between Lp(a),
inflammatory state and echocardiographic characteristics in patients after successful electrical cardioversion (EC) of
persistent AF. We also tried to investigate the role of Lp(a) as a possible prognostic factor for AF recurrence after
successful EC.
Results: Data of 79 patients admitted due to planned EC was analyzed. After successful procedure patients were
monitored for 2 years. For analytical purposes patients were divided in two groups according to AF recurrence.
There was no significant difference between Lp(a) levels in both groups. We also didn’t find any positive
correlation between Lp(a) and CRP levels, as well as between Lp(a) levels and left atrium diameter. For logistic and
survival analysis optimal cut-off value of Lp(a) ≥ 0.32 (upper quartile) was used. In logistic regression model with AF
recurrence as dependent variable Lp(a) didn’t show any statistically significant association with AF recurrence.
Survival analysis showed slightly higher AF recurrence rate in group with higher Lp(a) levels but not to the level of
statistical significance (log rank test, p = 0.62).
Conclusions: We weren’t able to confirm the association between Lp(a) levels and AF recurrence, inflammation
and left atrium diameter in patients after successful EC of persistent AF. Further studies are needed to elucidate the
role of Lp(a) in this clinical setting.
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Introduction
Atrial fibrillation (AF) is one of major causes for morbidity
and hospitalization [1]. It is also important risk factor for
thrombembolic complications and cerebrovascular disease
[2]. Existing data strongly support its connection with
ishemic heart disease, arterial hypertension, heart failure,
obesity and metabolic syndrome [3-7]. In past years few
studies tried to elucidate the association between AF and
lipoprotein(a), particularly in connection with thrombem-
bolic complications [8,9]. Major component of lipoprotein
(a), or Lp(a) is large glycoprotein molecule named apopro-
tein(a), which is produced in hepatocytes. It binds with
apo B100 component of LDL to form Lp(a). It was sug-
gested that apoprotein(a) because of its homology to plas-
minogen interferes with fibrinolytic system and hence
modulates thrombogenic activity in plasma [10]. Conco-
mitantly in AF patients extensive inflammation takes
place, which interferes with coagulation as well as oxida-
tion [11]. It was also shown that levels of Lp(a) correlate
with inflammatory state and coagulation disorders [12].
However a connection between Lp(a) and AF could not be
e s t a b l i s h e d[ 1 3 ] .I nt h i ss t u d yw ee v a l u a t e dt h ep o s s i b l e
interaction between Lp(a), cholesterol levels and inflam-
matory state in patients after successful electrical cardio-
version (EC) of persistent AF. We also tried to investigate
t h er o l eo fL p ( a )a sap o s s i b l ep r o g n o s t i cf a c t o rf o rA F
recurrence after successful EC.
Results
85 consecutive patients were included in analysis. We
lost 6 patients in follow-up period, so finally data of 79
patients was analyzed. Patients were followed for 2 years.
Baseline characteristics are displayed in Table 1. In group
of patients with recurrent AF we observed a significantly
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sinus rhythm we observed a greater proportion of
patients treated with amiodarone, but not to the level of
statistical significance. There were no other major differ-
ences between both groups, including Lp(a) levels. We
also didn’t find any positive correlation between Lp(a)
and CRP levels, as well as between Lp(a) levels and left
atrium diameter. For purposes of univariate, multivariate
and survival analysis optimal cut-off value of Lp(a) ≥ 0.32
(upper quartile) was used. In logistic regression model
with AF recurrence as dependent variable and Lp(a),
CRP, age, sex, duration of AF, arterial hypertension, dia-
betes, ischemic heart disease, echocardiographic mea-
surements and concomitant medications as independent
covariates, Lp(a) didn’t show any statistically significant
association with AF recurrence.
Survival analysis showed slightly higher AF recurrence
rate in group with higher Lp(a) levels but not to the
level of statistical significance (log rank test, p = 0.62;
Figure 1).
Discussion
In present study we tried to evaluate the possible con-
nection between plasma Lp(a) levels and AF. Despite
relatively large study population and long observation
period we didn’t find any positive correlation that would
confirm the role of Lp(a) in connection to AF. We also
didn’t find any correlation between Lp(a) levels and
inflammatory status in our patients. After performing
survival analysis we found only slightly higher AF recur-
rence rate in group of patients with higher Lp(a) levels,
but not to the level of statistical significance.
Table 1 Patients characteristics
All patients (n = 79) AF recurrence (n = 47) Sinus rhythm
(n = 32)
P value
Duration of AF 6.3 ± 9.3 8.0 ± 11.5 3.8 ± 3.0 <0.05
Age 62 ± 12 61 ± 14 64 ± 10 0.38
Sex 53 (67.1%) 35 (74.5%) 18 (56.3%) 0.14
Ishemic heart disease 9 (11.4%) 4 (8.5%) 5 (15.6%) 0.27
Arterial hypertension 58 (73.4%) 36 (76.6%) 22 (68.8%) 0.45
Diabetes 3 (3.8%) 0 3 (9.4%) 0.06
Treatment
- Amiodarone 60 (75.9%) 32 (68.1%) 28 (87.5%) 0.06
- Propafenone 19 (24.1%) 13 (27.7%) 6 (18.8%) 0.43
- Beta blocker 23 (29.1%) 17 (36.2%) 6 (18.8%) 0.13
-Angiotensin receptor blocker 5 (6.3%) 3 (6.4%) 2 (6.3%) 1.0
- ACE inhibitor 51 (64.4%) 32 (68.1%) 19 (59.4%) 0.48
- Statin 20 (25.3%) 9 (19.1%) 11 (34.4%) 0.19
Cholesterol levels (mmol/L) 5.1 ± 0.9 5.3 ± 1.1 4.9 ± 0.6 0.22
CRP (mg/L) 5.6 ± 7.4 5.1 ± 6.6 6.2 ± 8.6 0.61
Lp(a) (g/L) 0.21 ± 0.24 0.22 ± 0.23 0.19 ± 0.25 0.61
Ejection fraction (%) 51 ± 8 52 ± 8 50 ± 10 0.47
Mitral regurgitation
(stage 2 or higher)
14 (17.7%) 11 (23.4%) 3 (9.4%) 0.14
Left atrium dimension 5.2 ± 0.8 5.4 ± 0.7 5.1 ± 1.0 0.20
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Figure 1 Kaplan-Meier survival curves according to Lp(a) levels
(p = 0.62; log rank test).
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Page 2 of 4Our results are similar to conclusions of previous study
conducted by Diaz-Peromingo et al., who also didn’t find
any relationship between Lp(a) levels and AF [13]. They
compared 101 patients with AF and 101 patients with
sinus rhythm in control group. They found a higher total
cholesterol/HDL ratio in group of patients with AF, how-
ever there were no differences between both groups
when comparing levels of Lp(a). They concluded that at
least in part their results were influenced by ethnic char-
acteristics, since data exists that L(p)a levels are higher in
Afro-American and Hispanic population when compared
to Caucasians.
Many studies have tried to evaluate the role of Lp(a) in
different clinical settings. It was proven that higher levels
of Lp(a) are connected with cerebral ischemia and cere-
brovascular disease [14]. Igarashi et al. concluded in their
study that patients with AF and left atrial thrombus had
higher levels of Lp(a) [9]. This could partly be explained
by hypothesis that apoprotein(a) due to its similarity with
plasminogen interferes with fybrinolitic system [10].
Unfortunately in our study we weren’t able to follow coa-
gulation parameters and clinical events, what could give
further useful information about the role of Lp(a) in
patients with AF. We also weren’t able to prove the asso-
ciation between Lp(a) and inflammation, even though
t h e r ei sd a t at h a tt h i sc o n n e c t i o ne x i s t s[ 1 2 , 1 5 ] .O nt h e
other hand this could to some extent explain the lack of
any significant effect of Lp(a) in our patients. It is possi-
ble that in patients with higher level of inflammation
there would be stronger association between AF and
levels of Lp(a). We also found significantly prolonged
duration time of AF prior to EC in our group with recur-
rent AF. It is possible that this could have a certain
impact on our results. Since it was already stated that
time to cardioversion predicts the recurrence rate after
successful EC, perhaps in different clinical settings the
role of Lp(a) could be clarified to greater extent.
Conclusions
In present study we weren’t able to confirm any associa-
tion between Lp(a) levels and AF recurrence, inflammation
and left atrium diameter in patients after successful EC of
persistent AF. Further studies are needed to elucidate the
role of Lp(a) in this clinical setting, preferably in patients
with higher level of inflammation or developed
atherosclerosis.
Methods
This is a retrospective study of patients admitted for
planned EC between January 2003 and December 2003.
Data collection from hospital’s documentation database
was made accordingly to hospital ethics policy. Inclusion
criteria were AF lasting more than 7 days and successful
EC. Patients were excluded, if they had thyroid dysfunction,
chronic inflammatory condition (like rheumatoid arthritis),
implanted heart valve, pacemaker or cardioverter-defibrilla-
tor. They were also excluded if they had previous radiofre-
quency ablation of atrial arrhythmia.
Anticoagulant treatment was prescribed according to
current guidelines and antiarrhythmic therapy was given
according to clinician’s decision. After admittance patients
were fasted overnight. Blood sample was then drawn from
antecubital vein. Electrical cardioversion was performed
under sedation with propofol. After successful procedure
patients were monitored for another 24 hours. Patients
where AF recurrence was noticed within 24 hours were
excluded from further analysis. Follow-up consisted from
regular visits in our outpatient clinic every 1 to 6 months.
12-lead ECG was then recorded, history was taken and
clinical examination was performed. In case of symptoms
suggestive of AF recurrence 24 hour Holter was recorded.
Patients were also advised to visit emergency department
in case of palpitations. Documented AF was considered as
a study end point.
Patients were divided in two groups according to AF
recurrence. Continuous variables between both groups
were compared using t test and categorical variables with
chi square test. For correlation analysis Spearman’sr a n k
correlation coefficient was used. We divided Lp(a) levels
in quartiles in order to assess the discrimination ability of
Lp(a) for AF recurrence. Logistic regression model was
used to assess predictors of AF recurrence. For survival
analysis we used the Kaplan-Meier method with log rank
test. Continuous variables are expressed as mean ± SD
and categorical as percentages. A p value of < 0.05 was
considered for statistically significant. Statistical analysis
was performed using the SPSS 13.0 statistical package
(SPSS; Chicago, IL).
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